01 — At a Glance
The Pharma King Who Just Tripped on Stairs
- 52-Week High / Low₹1,673 / ₹1,282
- Q3 FY26 Revenue₹7,074 Cr
- Q3 FY26 PAT₹884 Cr (Flat YoY)
- Quarterly EPS₹8.37
- Annualised EPS (Q3×4)₹33.48
- Book Value₹408
- Price to Book3.24x
- Dividend Yield0.98%
- Net Cash Position₹10,229 Cr
- Return (3 Months)-13.1%
The Headline: Cipla reported Q3 FY26 revenue of ₹7,074 crore (flat YoY), PAT of ₹884 crore, and EPS of ₹8.37. But here’s the thing: the real story isn’t in the earnings. It’s in the two elephants standing in the boardroom. Lanreotide production is halted. Revlimid is dying. And the stock has crashed 13% in three months. Management says “transition year.” Analysts say “pray.”
02 — Introduction
The Pharma Giant Playing Russian Roulette with Two Bullets
Cipla is India’s third-largest pharmaceutical company by market share. It makes respiratory drugs that doctors swear by, anti-infectives that save lives, and in the US market, some obscure generic drugs that make extraordinary money. Founded in 1935 by Yusuf Hamied — India’s own pharmaceutical freedom fighter — Cipla has spent 90 years quietly becoming the backbone of generic pharma globally.
But Q3 FY26 just walked in and kicked the legs out from under that legacy. Two of Cipla’s biggest cash generators are simultaneously imploding. Generic Revlimid (lenalidomide) — a ₹1,000+ crore annual revenue earner — is facing patent cliff and declining rapidly. And Lanreotide, the company’s second-largest revenue contributor, just went into production arrest because its supplier in Greece got slapped with an FDA OAI (Official Action Indicated) status. That’s pharma-speak for “your facility is broken, figure it out.”
Management went on the January 2026 concall and said everything is “transition year” and “pipeline looks closer.” Translation: pray that US respiratory launches happen on time, or this stock will crack like a dropping egg.
So what’s actually happening inside Cipla? Is this the beginning of a reset, or the start of a value destruction story? Let’s dig through the data, the drama, and the real operational issues. Because right now, at a 22.4x P/E with margin compression and two product cliffs, the math doesn’t defend the valuation.
Concall Context (Jan 2026): Management acknowledged “lower-than-anticipated Lanreotide performance” and that EBITDA was “1.5–2% below internal expectations” due to supply issues and planned R&D spend increases for US launches.
03 — Business Model: Pills, Generics & Prayers
How Does Cipla Actually Make Money?
Cipla is a classic generic pharmaceutical company with four geographic revenue engines: India (43% of FY25 revenue), North America (26%), South Africa/SAGA (14%), and EMEU (13%). It sells 1,500+ products across 65 therapeutic categories in 170+ countries. The diversification sounds beautiful on paper. Reality is messier.
In India, Cipla dominates respiratory drugs (22.2% market share, #1 rank) and holds strong positions in cardiac, urology, and anti-infectives. It has 22 brands in the top 300 IPM brands and 30 brands generating over ₹100 crore annually. The company is chasing “One-India” growth by pushing chronic therapies (diabetes, cardiac) and launching trendy new products like Afrezza (inhaled insulin) and Yurpeak (tirzepatide for obesity). Smart moves. But India pricing is brutal, and margins never expand.
In North America, Cipla is a generics machine. It had a ₹931 crore ($112m) US business in FY25, growing at 24% CAGR since FY15. The problem? That growth was partly sustained by generic Revlimid, a cancer drug that earned Cipla potentially ₹1,000+ crores annually. But Revlimid’s patent is eroding. Market saturation is real. And now Cipla needs to replace that revenue with new launches. Good luck with that.
India Revenue43%Branded Rx
North America27%Generics Hub
SAGA Region14%Growing Mkt
EMEU13%Stable Base
API Business & Scale: Cipla manufactures 200+ generic APIs supplied to 62 countries. It’s a preferred partner to major generic firms. But API contributes just 2% to consolidated revenue (down from 6% in FY15). The margins are thin. The competition is blood-soaked. Most pharma companies quietly exit this segment. Cipla is still trying to make it work.
💬 Do you think Cipla’s US respiratory launches will actually offset the Revlimid cliff, or is management being overly optimistic? Drop your view!
04 — Financials Overview: Q3 FY26
The Numbers (And Why They’re Screaming SOS)
Result type: Quarterly Results | Q3 FY26 EPS: ₹8.37 | Annualised EPS (Q3×4): ₹33.48 | Full-year TTM EPS: ₹56.29
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 7,074 | 7,073 | 7,589 | 0.02% | -6.8% |
| Operating Profit | 1,255 | 1,989 | 1,895 | -36.9% | -33.8% |
| OPM % | 18% | 28% | 25% | -1000 bps | -700 bps |
| PAT | 884 | 1,575 | 1,353 | -43.9% | -34.7% |
| EPS (₹) | 8.37 | 19.45 | 16.73 | -56.9% | -49.9% |
⚠️ The Elephant in the Room: Revenue is flat, but operating profit crashed 36.9% YoY. OPM compressed 1,000 basis points from 28% to 18%. PAT fell 43.9% YoY. EPS is down 57% YoY. Management attributed this to: (1) Lanreotide supply disruption (production pause for remediation), (2) lower generic Revlimid contribution, and (3) higher R&D spend (₹494 crore, +37% YoY) for US launches. The concall was clear: this is a “transition year.”
05 — Valuation: Fair Value Range
What’s This Pharma Giant Worth When It’s Falling Apart?
Join 10,000+ investors who read this every week.
